OrthoPediatrics Corp. (KIDS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KIDS SEC filings page.
OrthoPediatrics Corp. (KIDS) reported $252.7M in revenue over the twelve months to Jun 30, 2026, up 14.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue has more than doubled, but persistent operating losses and continued investment show growth still requires substantial funding.
Across the reported period, gross margin stayed broadly stable while operating margin remained negative, indicating that scale has not yet transformed the cost structure. In FY2025, operating cash flow improved to-$4.9M while free cash flow remained-$16.0M after capital spending, so operations approached cash neutrality but reinvestment still consumed cash.
The business is growing without yet converting scale into operating profit: FY2025 revenue reached
Long-term debt rose from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of OrthoPediatrics Corp.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
OrthoPediatrics Corp. has an operating margin of -16.6%, meaning the company loses $17 on every $100 of revenue. This results in a profitability score of 37/100. This is up from -17.1% the prior year.
OrthoPediatrics Corp.'s revenue surged 15.4% year-over-year to $236.3M, reflecting rapid business expansion. This strong growth earns a score of 87/100.
OrthoPediatrics Corp. carries a low D/E ratio of 0.29, meaning only $0.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 70/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.55, OrthoPediatrics Corp. holds $5.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 93/100.
OrthoPediatrics Corp.'s operations used $4.9M of cash, and capex of $11.1M added to the outflow, for a free cash flow shortfall of $16.0M. This results in a cash flow score of 9/100.
OrthoPediatrics Corp. posts a -11.4% return on equity (ROE), meaning it loses $11 for every $100 of shareholders' equity. This results in a returns score of 41/100. This is down from -10.7% the prior year.
OrthoPediatrics Corp. scores 2.14, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($593.0M) relative to total liabilities ($162.0M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
OrthoPediatrics Corp. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
OrthoPediatrics Corp. reported a net loss of $39.6M while operations used $4.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
OrthoPediatrics Corp. reported an operating loss of $39.2M against $27K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
OrthoPediatrics Corp. generated $70.5M in revenue in Q2 2026. This represents an increase of 15.4% from the same quarter a year earlier. Against the prior quarter it is up 18.8%.
OrthoPediatrics Corp.'s EBITDA was $1.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 129.9% from the same quarter a year earlier. Against the prior quarter it is up 162.7%.
OrthoPediatrics Corp. reported -$7.2M in net income in Q2 2026. This represents a decrease of 0.7% from the same quarter a year earlier. Against the prior quarter it is up 33.0%.
OrthoPediatrics Corp. earned -$0.30 per diluted share (EPS) in Q2 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 33.3%.
Cash & Balance Sheet
OrthoPediatrics Corp. recorded an outflow of $3.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 77.6% from the same quarter a year earlier. Against the prior quarter it is up 38.2%.
OrthoPediatrics Corp. held $17.0M in cash against $99.5M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
OrthoPediatrics Corp.'s gross margin was 74.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.
OrthoPediatrics Corp.'s operating margin was -5.8% in Q2 2026, reflecting core business profitability. This is up 11.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.3 percentage points.
OrthoPediatrics Corp.'s net profit margin was -10.2% in Q2 2026, showing the share of revenue converted to profit. This is up 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.8 percentage points.
OrthoPediatrics Corp.'s ROE was -2.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
Capital Allocation
OrthoPediatrics Corp. invested $2.3M in research and development in Q2 2026. This represents an increase of 7.7% from the same quarter a year earlier. Against the prior quarter it is up 4.2%.
OrthoPediatrics Corp. invested $4.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 17.4% from the same quarter a year earlier. Against the prior quarter it is up 129.8%.
Not reported for Q2 2026.
KIDS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.5M+15.4% | $59.4M+13.3% | $61.6M+17.0% | $61.3M+12.2% | $61.1M+15.7% | $52.4M+17.3% | $52.7M+40.0% | $54.6M+36.5% |
| Cost of Revenue | $18.1M+6.3% | $16.0M+12.9% | $16.5M-3.5% | $16.0M+10.1% | $17.1M+42.2% | $14.1M+13.1% | $17.1M+56.9% | $14.5M+60.9% |
| Gross Profit | $52.4M+19.0% | $43.4M+13.4% | $45.1M+26.8% | $45.3M+13.0% | $44.0M+7.9% | $38.3M+18.9% | $35.6M+33.1% | $40.1M+29.4% |
| R&D Expenses | $2.3M+7.7% | $2.2M-5.1% | $2.3M-22.5% | $2.3M-9.5% | $2.2M-15.1% | $2.4M-21.6% | $2.9M-0.2% | $2.6M+0.6% |
| SG&A Expenses | $32.8M+7.8% | $31.0M+2.5% | $30.0M+22.6% | $29.2M+10.9% | $30.4M+11.4% | $30.3M+22.4% | $24.4M+28.2% | $26.3M+46.3% |
| Operating Income | -$4.1M+61.8% | -$8.3M+24.1% | -$8.2M+41.9% | -$9.4M-69.4% | -$10.7M-88.1% | -$11.0M-12.9% | -$14.1M-74.2% | -$5.6M-23.5% |
| EBITDA | $1.6M+129.9% | -$2.6M+55.9% | -$2.6M+74.5% | -$4.1M-1343.7% | -$5.5M-518.6% | -$5.9M-26.4% | -$10.1M-249.5% | -$286K-20.2% |
| Interest Expense | $2.5M+97.0% | $1.7M+32.5% | -$4.5M-171.1% | $2.0M+112.0% | $1.3M+204.8% | $1.3M+274.3% | -$1.7M-16800.0% | $945K+9350.0% |
| Income Tax | $234K+377.6% | -$171K-187.2% | $340K+200.0% | -$125K+89.7% | $49K+372.2% | $196K+107.7% | -$340K-60.4% | -$1.2M-243.5% |
| Net Income | -$7.2M-0.7% | -$10.7M-0.3% | -$10.1M+37.1% | -$11.8M-48.7% | -$7.1M-18.0% | -$10.7M-36.6% | -$16.1M-140.2% | -$7.9M-72.5% |
| EPS (Basic) | -$0.300.0% | -$0.45+2.2% | -$0.43+38.6% | -$0.50-47.1% | -$0.30-15.4% | -$0.46-35.3% | -$0.70-141.4% | -$0.34-70.0% |
| EPS (Diluted) | -$0.300.0% | -$0.45+2.2% | -$0.43+38.6% | -$0.50-47.1% | -$0.30-15.4% | -$0.46-35.3% | -$0.70-141.4% | -$0.34-70.0% |
| Diluted Shares (Avg) | 24M+2.5% | 24M+2.0% | N/A | 24M+1.7% | 23M+1.4% | 23M+1.8% | N/A | 23M+1.8% |
KIDS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $511.4M+1.5% | $502.2M+6.8% | $508.6M+7.5% | $493.5M+0.9% | $503.6M+16.9% | $470.3M+7.6% | $473.2M+7.9% | $489.3M+13.1% |
| Current Assets | $252.5M-2.0% | $245.9M+5.9% | $256.4M+8.1% | $245.9M-1.0% | $257.7M+33.0% | $232.1M+13.9% | $237.2M+4.7% | $248.3M+9.8% |
| Cash & Equivalents | $17.0M-61.8% | $12.2M-63.5% | $19.6M-55.4% | $16.8M-67.0% | $44.6M+54.0% | $33.4M+54.8% | $43.8M+41.1% | $51.0M+379.8% |
| Short-Term Investments | $28.9M+12.8% | $36.6M+44.5% | $41.3M+65.1% | $40.9M+63.5% | $25.6M | $25.3M-3.1% | $25.0M-49.2% | $25.0M-65.1% |
| Inventory | $137.6M+9.8% | $134.0M+11.9% | $133.8M+14.3% | $128.8M+6.5% | $125.3M+7.6% | $119.8M+6.3% | $117.0M+10.5% | $120.9M+20.3% |
| Accounts Receivable | $61.0M+13.3% | $54.4M+23.7% | $53.8M+27.1% | $51.3M+19.7% | $53.8M+28.0% | $44.0M+21.3% | $42.4M+22.4% | $42.8M+13.8% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $118.5M+19.6% | $115.2M+23.0% | $109.3M+16.4% | $103.6M+13.5% | $99.0M+9.4% | $93.7M+2.4% | $93.8M+12.1% | $91.3M+12.8% |
| Total Liabilities | $167.8M+13.3% | $163.5M+32.8% | $162.0M+36.6% | $144.2M+21.8% | $148.1M+149.0% | $123.1M+84.8% | $118.6M+92.2% | $118.4M+103.7% |
| Current Liabilities | $52.9M+36.7% | $47.2M+25.8% | $46.2M+36.0% | $33.2M-4.0% | $38.7M-2.3% | $37.5M-18.1% | $34.0M-18.5% | $34.6M-27.8% |
| Non-Current Liabilities | $114.9M+5.0% | $116.3M+35.9% | $115.8M+36.8% | $110.9M+32.5% | $109.4M+449.9% | $85.6M+311.9% | $84.7M+322.3% | $83.8M+722.0% |
| Long-Term Debt | $99.5M+2.5% | $100.4M+37.5% | $99.8M+36.8% | $99.2M+36.8% | $97.0M+891.7% | $73.0M+619.4% | $73.0M+636.3% | $72.5M |
| Total Equity | $343.6M-3.3% | $338.7M-2.4% | $346.6M-2.2% | $349.3M-5.8% | $355.5M-4.2% | $347.1M-6.3% | $354.6M-6.0% | $370.9M-0.9% |
| Retained Earnings | -$293.1M-15.7% | -$285.9M-16.1% | -$275.2M-16.8% | -$265.1M-20.8% | -$253.3M-19.7% | -$246.2M-19.8% | -$235.6M-19.1% | -$219.5M-14.9% |
KIDS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $928K+108.9% | -$3.3M+20.9% | $10.3M+359.5% | -$581K+94.3% | -$10.5M-71.7% | -$4.2M+37.9% | -$4.0M+47.1% | -$10.3M-18.6% |
| Depreciation & Amortization | $5.7M+10.4% | $5.7M+13.3% | $5.6M+40.3% | $5.3M+0.4% | $5.2M+8.2% | $5.0M+0.4% | $4.0M-23.0% | $5.3M+23.7% |
| Stock-Based Compensation | N/A | $4.0M+3.2% | N/A | N/A | N/A | $3.9M+37.9% | N/A | N/A |
| Capital Expenditures | $4.0M+17.4% | $1.8M-58.4% | $599K+128.6% | $2.8M+105.6% | $3.4M-48.5% | $4.2M-34.6% | -$262K-93.2% | $1.4M-44.3% |
| Free Cash Flow | -$3.1M+77.6% | -$5.0M+39.8% | $9.7M+329.4% | -$3.4M+70.7% | -$13.9M-8.9% | -$8.4M+36.3% | -$4.2M+62.7% | -$11.7M-4.6% |
| Investing Cash Flow | $5.0M+241.0% | -$3.8M+36.7% | -$7.3M-201.0% | -$26.8M-0.3% | -$3.5M-118.0% | -$6.0M-62.7% | -$2.4M-113.5% | -$26.8M-376.9% |
| Financing Cash Flow | -$737K-103.0% | -$614K-387.3% | -$417K+22.9% | -$282K-100.5% | $24.8M+680.9% | -$126K+78.0% | -$541K-105.8% | $58.5M+390220.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
KIDS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.3%+2.2pp | 73.1%+0.1pp | 73.2%+5.7pp | 73.9%+0.5pp | 72.1%-5.2pp | 73.0%+1.0pp | 67.5%-3.5pp | 73.4%-4.0pp |
| Operating Margin | -5.8%+11.7pp | -14.0%+6.9pp | -13.3%+13.4pp | -15.4%-5.2pp | -17.4%-6.7pp | -20.9%+0.8pp | -26.7%-5.3pp | -10.2%+1.1pp |
| Net Margin | -10.2%+1.5pp | -18.0%+2.3pp | -16.4%+14.1pp | -19.2%-4.7pp | -11.7%-0.2pp | -20.3%-2.9pp | -30.5%-12.7pp | -14.5%-3.0pp |
| Return on Equity | -2.1%-0.1pp | -3.2%-0.1pp | -2.9%+1.6pp | -3.4%-1.2pp | -2.0%-0.4pp | -3.1%-1.0pp | -4.5%-2.8pp | -2.1%-0.9pp |
| Return on Assets | -1.4%0.0pp | -2.1%+0.1pp | -2.0%+1.4pp | -2.4%-0.8pp | -1.4%0.0pp | -2.3%-0.5pp | -3.4%-1.9pp | -1.6%-0.6pp |
| Current Ratio | 4.78-1.9x | 5.21-1.0x | 5.55-1.4x | 7.40+0.2x | 6.66+1.8x | 6.19+1.7x | 6.98+1.5x | 7.17+2.5x |
| Debt-to-Equity | 0.290.0x | 0.30+0.1x | 0.29+0.1x | 0.28+0.1x | 0.27+0.2x | 0.21+0.2x | 0.21+0.2x | 0.200.0x |
| Asset Turnover | 0.140.0x | 0.120.0x | 0.120.0x | 0.120.0x | 0.120.0x | 0.110.0x | 0.110.0x | 0.110.0x |
| FCF Margin | -4.4%+18.4pp | -8.5%+7.5pp | 15.8%+23.9pp | -5.6%+15.8pp | -22.8%+1.4pp | -16.0%+13.4pp | -8.1%+22.2pp | -21.4%+6.5pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| OrthoPediatrics Corp. KIDS | FY2025 | $236.3M | -$39.6M | -16.8% | $593.0M | 56/100 |
| ZimVie Inc. ZIMV | FY2024 | $449.7M | -$25.8M | -5.7% | $535.7M | 23/100 |
| Treace Medical Concepts, Inc. TMCI | FY2025 | $212.7M | -$59.0M | -27.7% | $260.1M | 45/100 |
| Cytek Biosciences, Inc. CTKB | FY2025 | $201.5M | -$66.5M | -33.0% | $699.3M | 45/100 |
| Standard BioTools Inc. LAB | FY2025 | $85.3M | -$74.9M | -87.8% | $283.4M | 44/100 |
| Bioventus Inc. BVS | FY2025 | $568.1M | $22.7M | 4.0% | $894.8M | 42/100 |
Where OrthoPediatrics Corp. Ranks
Frequently Asked Questions
What is OrthoPediatrics Corp.'s annual revenue?
OrthoPediatrics Corp. (KIDS) reported $236.3M in total revenue for fiscal year 2025. This represents a 15.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is OrthoPediatrics Corp.'s revenue growing?
OrthoPediatrics Corp. (KIDS) revenue grew by 15.4% year-over-year, from $204.7M to $236.3M in fiscal year 2025.
Is OrthoPediatrics Corp. profitable?
No, OrthoPediatrics Corp. (KIDS) reported a net income of -$39.6M in fiscal year 2025, with a net profit margin of -16.8%.
What is OrthoPediatrics Corp.'s EBITDA?
OrthoPediatrics Corp. (KIDS) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does OrthoPediatrics Corp. have?
As of fiscal year 2025, OrthoPediatrics Corp. (KIDS) had $19.6M in cash and equivalents against $99.8M in long-term debt.
What is OrthoPediatrics Corp.'s gross margin?
OrthoPediatrics Corp. (KIDS) had a gross margin of 73.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is OrthoPediatrics Corp.'s operating margin?
OrthoPediatrics Corp. (KIDS) had an operating margin of -16.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is OrthoPediatrics Corp.'s net profit margin?
OrthoPediatrics Corp. (KIDS) had a net profit margin of -16.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is OrthoPediatrics Corp.'s return on equity (ROE)?
OrthoPediatrics Corp. (KIDS) has a return on equity of -11.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is OrthoPediatrics Corp.'s free cash flow?
OrthoPediatrics Corp. (KIDS) recorded an outflow of $16.0M in free cash flow during fiscal year 2025. This represents a 61.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is OrthoPediatrics Corp.'s operating cash flow?
OrthoPediatrics Corp. (KIDS) recorded an outflow of $4.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are OrthoPediatrics Corp.'s total assets?
OrthoPediatrics Corp. (KIDS) had $508.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are OrthoPediatrics Corp.'s capital expenditures?
OrthoPediatrics Corp. (KIDS) invested $11.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does OrthoPediatrics Corp. spend on research and development?
OrthoPediatrics Corp. (KIDS) invested $9.1M in research and development during fiscal year 2025.
What is OrthoPediatrics Corp.'s current ratio?
OrthoPediatrics Corp. (KIDS) had a current ratio of 5.55 as of fiscal year 2025, which is generally considered healthy.
What is OrthoPediatrics Corp.'s debt-to-equity ratio?
OrthoPediatrics Corp. (KIDS) had a debt-to-equity ratio of 0.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is OrthoPediatrics Corp.'s return on assets (ROA)?
OrthoPediatrics Corp. (KIDS) had a return on assets of -7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is OrthoPediatrics Corp.'s P/E ratio?
OrthoPediatrics Corp. (KIDS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $593.0M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is OrthoPediatrics Corp.'s price-to-sales ratio?
OrthoPediatrics Corp. (KIDS) trades at 2.3x sales, its market capitalization divided by revenue of $252.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $593.0M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is OrthoPediatrics Corp.'s Altman Z-Score?
OrthoPediatrics Corp. (KIDS) has an Altman Z-Score of 2.14, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is OrthoPediatrics Corp.'s Piotroski F-Score?
OrthoPediatrics Corp. (KIDS) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are OrthoPediatrics Corp.'s earnings high quality?
OrthoPediatrics Corp. (KIDS) reported a net loss of $39.6M while operations used $4.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can OrthoPediatrics Corp. cover its interest payments?
OrthoPediatrics Corp. (KIDS) reported an operating loss of $39.2M against $27K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is OrthoPediatrics Corp.?
OrthoPediatrics Corp. (KIDS) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.